Clinical Trials Browser

Phase 2 × Neoplasms, Germ Cell and Embryonal × Etoposide × Clear all

Brain Neoplasms, Carcinoma, Ependymoma, Histiocytosis, Langerhans-Cell, Medulloblastoma, Neoplasms, Neoplasms, Germ Cell and Embryonal, Neuroblastoma, Pinealoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

NCT01873326 2025-07-03

Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors

Phase 2 Active not recruiting

92 enrolled

Neoplasms, Germ Cell and Embryonal

NCT04804007 2025-04-18

Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT

Phase 2 Recruiting

64 enrolled

Nonseminomatous germ cell tumor, Neoplasms, Germ Cell and Embryonal

NCT06309732 2024-03-13

GAMEC-II

Phase 2 Completed

36 enrolled

Genitourinary

Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms

NCT00864318 2021-01-12

TICE

Phase 2 Completed

101 enrolled

Neoplasms, Germ Cell and Embryonal, Recurrence

NCT02161692 2014-06-12

Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors

Phase 2 Completed

Genitourinary

Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms

Clinical Trials

AflacST1502

Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors

Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT

GAMEC-II

TICE

Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors